Role of LRF/Pokemon in lineage fate decisions

Blood

Volumn 121, Issue 15, 2013, Pages 2845-2853

  Lunardi, Andrea ^a   Guarnerio, Jlenia ^a   Wang, Guocan ^a   Maeda, Takahiro ^b   Pandolfi, Pier Paolo ^a  

^a BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

KRUPPEL LIKE FACTOR; LEUKEMIA RELATED FACTOR; NOTCH RECEPTOR; POKEMON PROTEIN; PROTEIN BCL 6; TRANSCRIPTION FACTOR; UNCLASSIFIED DRUG; DNA BINDING PROTEIN; TUMOR SUPPRESSOR PROTEIN; ZBTB7A PROTEIN, HUMAN; ZINC FINGER PROTEIN;

B LYMPHOCYTE DIFFERENTIATION; BONE MARROW CELL; CELL FATE; CELL LINEAGE; ERYTHROID CELL; GENE EXPRESSION; HUMAN; LYMPHOID CELL; NONHUMAN; OSTEOCLAST; PRIORITY JOURNAL; PROTEIN INTERACTION; PROTEIN STRUCTURE; REVIEW; ROLE PLAYING; BIOLOGICAL MODEL; CELL DIFFERENTIATION; CELL TRANSFORMATION; GENETICS; HEMATOPOIESIS; LYMPHOMA; METABOLISM; PATHOLOGY;

CELL DIFFERENTIATION; CELL LINEAGE; CELL TRANSFORMATION, NEOPLASTIC; DNA-BINDING PROTEINS; HEMATOPOIESIS; HUMANS; LYMPHOMA; MODELS, GENETIC; TRANSCRIPTION FACTORS; TUMOR SUPPRESSOR PROTEINS; ZINC FINGERS;

MLCS; MLOWN;

EID: 84879423061     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2012-11-292037     Document Type: Review

References (96)

1. Restifo LL, White K. Mutations in a steroid hormone-regulated gene disrupt the metamorphosis of the central nervous system in Drosophila. Dev Biol. 1991;148(1):174-194.
2. Karim FD, Guild GM, Thummel CS. The Drosophila Broad-Complex plays a key role in controlling ecdysone-regulated gene expression at the onset of metamorphosis. Development. 1993;118(3):977-988.
3. Xiong WC, Montell C. tramtrack is a transcriptional repressor required for cell fate determination in the Drosophila eye. Genes Dev. 1993;7(6):1085-1096.
4. Sahut-Barnola I, Godt D, Laski FA, et al. Drosophila ovary morphogenesis: analysis of terminal filament formation and identification of a gene required for this process. Dev Biol. 1995;170(1):127-135.
5. Godt D, Couderc JL, Cramton SE, et al. Pattern formation in the limbs of Drosophila: bric à brac is expressed in both a gradient and a wave-like pattern and is required for specification and proper segmentation of the tarsus. Development. 1993;119(3):799-812.
6. Maeng O, Son W, Chung J, et al. The BTB/POZ-ZF transcription factor dPLZF is involved in Ras/ERK signaling during Drosophila wing development. Mol Cells. 2012;33(5):457-463.
7. Lee SU, Maeda T. POK/ZBTB proteins: an emerging family of proteins that regulate lymphoid development and function. Immunol Rev. 2012;247(1):107-119.
8. Kelly KF, Daniel JM. POZ for effect - POZ-ZF transcription factors in cancer and development. Trends Cell Biol. 2006;16(11):578-587.
9. Costoya JA. Functional analysis of the role of POK transcriptional repressors. Brief Funct Genomics Proteomics. 2007;6(1):8-18.
10. Cui J, Yang Y, Zhang C, et al. FBI-1 functions as a novel AR co-repressor in prostate cancer cells. Cell Mol Life Sci. 2011;68(6):1091-1103.
11. Davies JM, Hawe N, Kabarowski J, et al. Novel BTB/POZ domain zinc-finger protein, LRF, is a potential target of the LAZ-3/BCL-6 oncogene. Oncogene. 1999;18(2):365-375.
12. Choi WI, Kim Y, Kim Y, et al. Eukaryotic translation initiator protein 1A isoform, CCS-3, enhances the transcriptional repression of p21CIP1 by proto-oncogene FBI-1 (Pokemon/ZBTB7A). Cell Physiol Biochem. 2009;23(4-6):359-370.
13. Lee DK, Suh D, Edenberg HJ, et al. POZ domain transcription factor, FBI-1, represses transcription of ADH5/FDH by interacting with the zinc finger and interfering with DNA binding activity of Sp1. J Biol Chem. 2002;277(30):26761-26768.
14. Roh HE, Lee MN, Jeon BN, et al. Regulation of pokemon 1 activity by sumoylation. Cell Physiol Biochem. 2007;20(1-4):167-180.
15. Beausoleil SA, Jedrychowski M, Schwartz D, et al. Large-scale characterization of HeLa cell nuclear phosphoproteins. Proc Natl Acad Sci USA. 2004;101(33):12130-12135.
16. Dephoure N, Zhou C, Villén J, et al. A quantitative atlas of mitotic phosphorylation. Proc Natl Acad Sci USA. 2008;105(31):10762-10767.
17. Mayya V, Han DK. Phosphoproteomics by mass spectrometry: insights, implications, applications and limitations. Expert Rev Proteomics. 2009;6(6):605-618.
18. Cantin GT, Yi W, Lu B, et al. Combining protein-based IMAC, peptide-based IMAC, and MudPIT for efficient phosphoproteomic analysis. J Proteome Res. 2008;7(3):1346-1351.
19. David G, Alland L, Hong SH, et al. Histone deacetylase associated with mSin3A mediates repression by the acute promyelocytic leukemia-associated PLZF protein. Oncogene. 1998;16(19):2549-2556.
20. Dhordain P, Lin RJ, Quief S, et al. The LAZ3 (BCL-6) oncoprotein recruits a SMRT/mSIN3A/histone deacetylase containing complex to mediate transcriptional repression. Nucleic Acids Res. 1998;26(20):4645-4651.
21. Maeda T, Hobbs RM, Merghoub T, et al. Role of the proto-oncogene Pokemon in cellular transformation and ARF repression. Nature. 2005;433(7023):278-285.
22. Pessler F, Hernandez N. Flexible DNA binding of the BTB/POZ-domain protein FBI-1. J Biol Chem. 2003;278(31):29327-29335.
23. Wang J, Zhuang J, Iyer S, et al. Sequence features and chromatin structure around the genomic regions bound by 119 human transcription factors. Genome Res. 2012;22(9):1798-1812.
24. Ye BH, Cattoretti G, Shen Q, et al. The BCL-6 proto-oncogene controls germinal-centre formation and Th2-type inflammation. Nat Genet. 1997;16(2):161-170.
25. Koken MH, Reid A, Quignon F, et al. Leukemia-associated retinoic acid receptor alpha fusion partners, PML and PLZF, heterodimerize and colocalize to nuclear bodies. Proc Natl Acad Sci USA. 1997;94(19):10255-10260.
26. Lo Coco F, Ye BH, Lista F, et al. Rearrangements of the BCL6 gene in diffuse large cell non-Hodgkin's lymphoma. Blood. 1994;83(7):1757-1759.
27. McConnell MJ, Chevallier N, Berkofsky-Fessler W, et al. Growth suppression by acute promyelocytic leukemia-associated protein PLZF is mediated by repression of c-myc expression. Mol Cell Biol. 2003;23(24):9375-9388.
28. He LZ, Bhaumik M, Tribioli C, et al. Two critical hits for promyelocytic leukemia. Mol Cell. 2000;6(5):1131-1141.
29. Rego EM, Ruggero D, Tribioli C, et al. Leukemia with distinct phenotypes in transgenic mice expressing PML/RAR alpha, PLZF/RAR alpha or NPM/RAR alpha. Oncogene. 2006;25(13):1974-1979.
30. Barna M, Pandolfi PP, Niswander L. Gli3 and Plzf cooperate in proximal limb patterning at early stages of limb development. Nature. 2005;436(7048):277-281.
31. Maeda T, Merghoub T, Hobbs RM, et al. Regulation of B versus T lymphoid lineage fate decision by the proto-oncogene LRF. Science. 2007;316(5826):860- 866.
32. Maeda T, Ito K, Merghoub T, et al. LRF is an essential downstream target of GATA1 in erythroid development and regulates BIM-dependent apoptosis. Dev Cell. 2009;17(4):527-540.
33. Hodge D, Coghill E, Keys J, et al. A global role for EKLF in definitive and primitive erythropoiesis. Blood. 2006;107(8):3359-3370.
34. Yu M, Riva L, Xie H, et al. Insights into GATA-1-mediated gene activation versus repression via genome-wide chromatin occupancy analysis. Mol Cell. 2009;36(4):682-695.
35. Lee SU, Maeda M, Ishikawa Y, et al. LRF-mediated Dll4 repression in erythroblasts is necessary for hematopoietic stem cell maintenance. Blood. 2013;121(6):918-929.
36. Pui JC, Allman D, Xu L, et al. Notch1 expression in early lymphopoiesis influences B versus T lineage determination. Immunity. 1999;11(3):299-308.
37. Carpenter AC, Grainger JR, Xiong Y, et al. The transcription factors Thpok and LRF are necessary and partly redundant for T helper cell differentiation. Immunity. 2012;37(4):622-633.
38. Sun G, Liu X, Mercado P, et al. The zinc finger protein cKrox directs CD4 lineage differentiation during intrathymic T cell positive selection. Nat Immunol. 2005;6(4):373-381.
39. He X, He X, Dave VP, et al. The zinc finger transcription factor Th-POK regulates CD4 versus CD8 T-cell lineage commitment. Nature. 2005;433(7028):826- 833.
40. Sakurai N, Maeda M, Lee SU, et al. The LRF transcription factor regulates mature B cell development and the germinal center response in mice. J Clin Invest. 2011;121(7):2583-2598.
41. Schofield R. The relationship between the spleen colony-forming cell and the haemopoietic stem cell. Blood Cells. 1978;4(1-2):7-25.
42. Wilson A, Oser GM, Jaworski M, et al. Dormant and self-renewing hematopoietic stem cells and their niches. Ann N Y Acad Sci. 2007;1106:64-75.
43. Fuchs E. Finding one's niche in the skin. Cell Stem Cell. 2009;4(6):499-502.
44. Yen TH, Wright NA. The gastrointestinal tract stem cell niche. Stem Cell Rev. 2006;2(3):203-212.
45. Doetsch F. A niche for adult neural stem cells. Curr Opin Genet Dev. 2003;13(5):543-550.
46. Spradling A, Drummond-Barbosa D, Kai T. Stem cells find their niche. Nature. 2001;414(6859):98-104.
47. Koch U, Fiorini E, Benedito R, et al. Delta-like 4 is the essential, nonredundant ligand for Notch1 during thymic T cell lineage commitment. J Exp Med. 2008;205(11):2515-2523.
48. Shutter JR, Scully S, Fan W, et al. Dll4, a novel Notch ligand expressed in arterial endothelium. Genes Dev. 2000;14(11):1313-1318.
49. Krebs LT, Xue Y, Norton CR, et al. Notch signaling is essential for vascular morphogenesis in mice. Genes Dev. 2000;14(11):1343-1352.
50. Duarte A, Hirashima M, Benedito R, et al. Dosage-sensitive requirement for mouse Dll4 in artery development. Genes Dev. 2004;18(20):2474-2478.
51. Liu J, Sato C, Cerletti M, et al. Notch signaling in the regulation of stem cell self-renewal and differentiation. Curr Top Dev Biol. 2010;92:367-409.
52. Pajcini KV, Speck NA, Pear WS. Notch signaling in mammalian hematopoietic stem cells. Leukemia. 2011;25(10):1525-1532.
53. Bigas A, D'Altri T, Espinosa L. The Notch pathway in hematopoietic stem cells. Curr Top Microbiol Immunol. 2012;360:1-18.
54. Sandy AR, Jones M, Maillard I. Notch signaling and development of the hematopoietic system. Adv Exp Med Biol. 2012;727:71-88.
55. Udagawa N, Takahashi N, Akatsu T, et al. Origin of osteoclasts: mature monocytes and macrophages are capable of differentiating into osteoclasts under a suitable microenvironment prepared by bone marrow-derived stromal cells. Proc Natl Acad Sci USA. 1990;87(18):7260-7264.
56. Kukita A, Kukita T, Ouchida M, et al. Osteoclast-derived zinc finger (OCZF) protein with POZ domain, a possible transcriptional repressor, is involved in osteoclastogenesis. Blood. 1999;94(6):1987-1997.
57. Yasuda H, Shima N, Nakagawa N, et al. Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL. Proc Natl Acad Sci USA. 1998;95(7):3597-3602.
58. Kong YY, Yoshida H, Sarosi I, et al. OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis. Nature. 1999;397(6717):315-323.
59. Luchin A, Suchting S, Merson T, et al. Genetic and physical interactions between Microphthalmia transcription factor and PU.1 are necessary for osteoclast gene expression and differentiation. J Biol Chem. 2001;276(39):36703-36710.
60. Tondravi MM, McKercher SR, Anderson K, et al. Osteopetrosis in mice lacking haematopoietic transcription factor PU.1. Nature. 1997;386(6620):81-84.
61. Teitelbaum SL, Ross FP. Genetic regulation of osteoclast development and function. Nat Rev Genet. 2003;4(8):638-649.
62. Insogna KL, Sahni M, Grey AB, et al. Colony-stimulating factor-1 induces cytoskeletal reorganization and c-src-dependent tyrosine phosphorylation of selected cellular proteins in rodent osteoclasts. J Clin Invest. 1997;100(10):2476-2485.
63. Kukita A, Kukita T, Nagata K, et al. The transcription factor FBI-1/OCZF/LRF is expressed in osteoclasts and regulates RANKL-induced osteoclast formation in vitro and in vivo. Arthritis Rheum. 2011;63(9):2744- 2754.
64. Tsuji-Takechi K, Negishi-Koga T, Sumiya E, et al. Stage-specific functions of leukemia/lymphoma-related factor (LRF) in the transcriptional control of osteoclast development. Proc Natl Acad Sci USA. 2012;109(7):2561- 2566.
65. Lengner CJ, Hassan MQ, Serra RW, et al. Nkx3.2-mediated repression of Runx2 promotes chondrogenic differentiation. J Biol Chem. 2005;280(16):15872- 15879.
66. Zhou G, Zheng Q, Engin F, et al. Dominance of SOX9 function over RUNX2 during skeletogenesis. Proc Natl Acad Sci USA. 2006;103(50):19004-19009.
67. Dy P, Wang W, Bhattaram P, et al. Sox9 directs hypertrophic maturation and blocks osteoblast differentiation of growth plate chondrocytes. Dev Cell. 2012;22(3):597-609.
68. Liu CJ, Zhang Y, Xu K, et al. Transcriptional activation of cartilage oligomeric matrix protein by Sox9, Sox5, and Sox6 transcription factors and CBP/p300 coactivators. Front Biosci. 2007;12:3899-3910.
69. Nagy A, Kénesi E, Rentsendorj O, et al. Evolutionarily conserved, growth plate zone-specific regulation of the matrilin-1 promoter: L-Sox5/Sox6 and Nfi factors bound near TATA finely tune activation by Sox9. Mol Cell Biol. 2011;31(4):686-699.
70. Aza-Carmona M, Shears DJ, Yuste-Checa P, et al. SHOX interacts with the chondrogenic transcription factors SOX5 and SOX6 to activate the aggrecan enhancer. Hum Mol Genet. 2011;20(8):1547-1559.
71. Dvir-Ginzberg M, Gagarina V, Lee EJ, et al. Regulation of cartilage-specific gene expression in human chondrocytes by SirT1 and nicotinamide phosphoribosyltransferase. J Biol Chem. 2008;283(52):36300-36310.
72. Liu CJ, Prazak L, Fajardo M, et al. Leukemia/lymphoma-related factor, a POZ domain-containing transcriptional repressor, interacts with histone deacetylase-1 and inhibits cartilage oligomeric matrix protein gene expression and chondrogenesis. J Biol Chem. 2004;279(45):47081-47091.
73. Zhang Y, Khan D, Delling J, Tobiasch E. Mechanisms underlying the osteo- and adipo-differentiation of human mesenchymal stem cells. ScientificWorldJournal. 2012;2012:793823.
74. Laudes M, Christodoulides C, Sewter C, et al. Role of the POZ zinc finger transcription factor FBI-1 in human and murine adipogenesis. J Biol Chem. 2004;279(12):11711-11718.
75. Laudes M, Bilkovski R, Oberhauser F, et al. Transcription factor FBI-1 acts as a dual regulator in adipogenesis by coordinated regulation of cyclin-A and E2F-4. J Mol Med (Berl). 2008;86(5):597-608.
76. Dobson NR, Moore RT, Tobin JE, et al. Leukemia/lymphoma-related factor regulates oligodendrocyte lineage cell differentiation in developing white matter. Glia. 2012;60(9):1378-1390.
77. Kovalovsky D, Uche OU, Eladad S, et al. The BTB-zinc finger transcriptional regulator PLZF controls the development of invariant natural killer T cell effector functions. Nat Immunol. 2008;9(9):1055-1064.
78. Costoya JA, Hobbs RM, Barna M, et al. Essential role of Plzf in maintenance of spermatogonial stem cells. Nat Genet. 2004;36(6):653-659.
79. Barna M, Hawe N, Niswander L, et al. Plzf regulates limb and axial skeletal patterning. Nat Genet. 2000;25(2):166-172.
80. Hobbs RM, Seandel M, Falciatori I, et al. Plzf regulates germline progenitor self-renewal by opposing mTORC1. Cell. 2010;142(3):468-479.
81. Hobbs RM, Fagoonee S, Papa A, et al. Functional antagonism between Sall4 and Plzf defines germline progenitors. Cell Stem Cell. 2012;10(3):284-298.
82. Dent AL, Shaffer AL, Yu X, et al. Control of inflammation, cytokine expression, and germinal center formation by BCL-6. Science. 1997;276(5312):589-592.
83. Phan RT, Dalla-Favera R. The BCL6 protooncogene suppresses p53 expression in germinal-centre B cells. Nature. 2004;432(7017):635-639.
84. Ranuncolo SM, Polo JM, Dierov J, et al. Bcl-6 mediates the germinal center B cell phenotype and lymphomagenesis through transcriptional repression of the DNA-damage sensor ATR. Nat Immunol. 2007;8(7):705-714.
85. Wlodarska I, Nooyen P, Maes B, et al. Frequent occurrence of BCL6 rearrangements in nodular lymphocyte predominance Hodgkin lymphoma but not in classical Hodgkin lymphoma. Blood. 2003;101(2):706-710.
86. Vredeveld LC, Rowland BD, Douma S, et al. Functional identification of LRF as an oncogene that bypasses RASV12-induced senescence via upregulation of CYCLIN E. Carcinogenesis. 2010;31(2):201-207.
87. Qu H, Qu D, Chen F, et al. ZBTB7 overexpression contributes to malignancy in breast cancer. Cancer Invest. 2010;28(6):672-678.
88. Apostolopoulou K, Pateras IS, Evangelou K, et al. Gene amplification is a relatively frequent event leading to ZBTB7A (Pokemon) overexpression in non-small cell lung cancer. J Pathol. 2007;213(3):294-302.
89. Zhao ZH, Wang SF, Yu L, et al. Overexpression of Pokemon in non-small cell lung cancer and foreshowing tumor biological behavior as well as clinical results. Lung Cancer. 2008;62(1):113-119.
90. Jiang L, Siu MK, Wong OG, et al. Overexpression of proto-oncogene FBI-1 activates membrane type 1-matrix metalloproteinase in association with adverse outcome in ovarian cancers. Mol Cancer. 2010;9:318.
91. Miller SJ, Jessen WJ, Mehta T, et al. Integrative genomic analyses of neurofibromatosis tumours identify SOX9 as a biomarker and survival gene. EMBO Mol Med. 2009;1(4):236-248.
92. Grabher C, von Boehmer H, Look AT. Notch 1 activation in the molecular pathogenesis of T-cell acute lymphoblastic leukaemia. Nat Rev Cancer. 2006;6(5):347-359.
93. Sjölund J, Manetopoulos C, Stockhausen MT, et al. The Notch pathway in cancer: differentiation gone awry. Eur J Cancer. 2005;41(17):2620-2629.
94. Zhou CH, Ye LP, Ye SX, et al. Clinical significance of SOX9 in human non-small cell lung cancer progression and overall patient survival. J Exp Clin Cancer Res. 2012;31:18.
95. Clemons NJ, Wang DH, Croagh D, et al. Sox9 drives columnar differentiation of esophageal squamous epithelium: a possible role in the pathogenesis of Barrett's esophagus. Am J Physiol Gastrointest Liver Physiol. 2012;303(12):G1335-G1346.
96. Wang L, He S, Yuan J, et al. Oncogenic role of SOX9 expression in human malignant glioma. Med Oncol. 2012;29(5):3484-3490.